NR3C1 and prostate carcinoma: Apart from their role in CRPC, glucocorticoids can also contribute to treatment failure in many other cancer types.[45,46] Understanding the tumorigenic effects of GR activation in other tumor types might provide useful insights and generate interesting hypotheses regarding the effects of GR in prostate cancer.